These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30836776)

  • 1. Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer.
    Nichols RC; Morris CG; Bryant C; Hoppe BS; Henderson RH; Mendenhall WM; Li Z; Costa JA; Williams CR; Mendenhall NP
    Cancer Invest; 2019; 37(2):85-89. PubMed ID: 30836776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression.
    Kil WJ; Nichols RC; Hoppe BS; Morris CG; Marcus RB; Mendenhall W; Mendenhall NP; Li Z; Costa JA; Williams CR; Henderson RH
    Acta Oncol; 2013 Apr; 52(3):492-7. PubMed ID: 23477360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression.
    Nichols RC; Morris CG; Hoppe BS; Henderson RH; Marcus RB; Mendenhall WM; Li Z; Williams CR; Costa JA; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1222-6. PubMed ID: 21570206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.
    Zagars GK; Pollack A; von Eschenbach AC
    Urology; 1997 Mar; 49(3):327-34. PubMed ID: 9123693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.
    Pastuszak AW; Khanna A; Badhiwala N; Morgentaler A; Hult M; Conners WP; Sarosdy MF; Yang C; Carrion R; Lipshultz LI; Khera M
    J Urol; 2015 Nov; 194(5):1271-6. PubMed ID: 26025500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.
    Ödén J; Eriksson K; Toma-Dasu I
    Med Phys; 2017 Mar; 44(3):810-822. PubMed ID: 28107554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Prostate Cancer Radiotherapy on Testosterone Level: A Systematic Review and Meta-analysis.
    Mortezaee K; Motallebzadeh E; Milajerdi A; Farhood B; Najafi M; Sahebkar A
    Anticancer Agents Med Chem; 2020; 20(6):636-642. PubMed ID: 31994469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in sexual function and serum testosterone levels in patients with prostate cancer after image-guided proton therapy.
    Hattori Y; Iwata H; Nakajima K; Nomura K; Hayashi K; Toshito T; Hashimoto S; Umemoto Y; Mizoe JE; Ogino H; Shibamoto Y
    J Radiat Res; 2021 May; 62(3):517-524. PubMed ID: 33675355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sperm preservation and neutron contamination following proton therapy for prostate cancer study.
    Hoppe BS; Harris S; Rhoton-Vlasak A; Bryant C; Morris CG; Dagan R; Nichols RC; Mendenhall WM; Henderson RH; Li Z; Mendenhall NP
    Acta Oncol; 2017 Jan; 56(1):17-20. PubMed ID: 27420031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.
    Kamada S; Sakamoto S; Ando K; Muroi A; Fuse M; Kawamura K; Imamoto T; Suzuki H; Nagata M; Nihei N; Akakura K; Ichikawa T
    J Urol; 2015 Nov; 194(5):1264-70. PubMed ID: 25861958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
    BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton therapy for prostate cancer: current state and future perspectives.
    Wu YY; Fan KH
    Br J Radiol; 2022 Mar; 95(1131):20210670. PubMed ID: 34558308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer: Interim Results of a Randomized Trial PCG GU 002.
    Vargas CE; Hartsell WF; Dunn M; Keole SR; Doh L; Eisenbeisz E; Larson GL
    Am J Clin Oncol; 2018 Feb; 41(2):115-120. PubMed ID: 26523442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between prostate cancer and serum testosterone levels.
    Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G
    Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer.
    Pompe RS; Karakiewicz PI; Zaffuto E; Smith A; Bandini M; Marchioni M; Tian Z; Leyh-Bannurah SR; Schiffmann J; Delouya G; Lambert C; Bahary JP; Beauchemin MC; Barkati M; Ménard C; Graefen M; Saad F; Tilki D; Taussky D
    J Sex Med; 2017 Jul; 14(7):876-882. PubMed ID: 28546065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.